Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study^*

References

• Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004;5:551-9
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9 (1Supp. 1):S37-44
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43 (2):111-17
   PubMed Web of Science ®Google Scholar
• Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007;57 (6 Suppl.):S130-5
   PubMed Web of Science ®Google Scholar
• Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22(5):417-42
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes EM, Oster G et al. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9
   PubMed Web of Science ®Google Scholar
• Dworkin RH, White R O’Connor, et al. Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster. Jam Geriatr Soc 2007;55:1168-75
   PubMed Web of Science ®Google Scholar
• Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005;6(5):317-25
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008;9:1-10
   Google Scholar
• Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997;157(11):1217-24
   PubMed Web of Science ®Google Scholar
• Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5:209-27
   PubMed Web of Science ®Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2(7):e164
   PubMed Web of Science ®Google Scholar
• Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008;9(1 Suppl. 1):S3-9
   PubMed Web of Science ®Google Scholar
• Pappagallo M, Haldey EJ. Pharmacological management of postherpetic neuralgia. CNS Drugs 2003;17(11):771-80
   PubMed Web of Science ®Google Scholar
• Galer BS. Myofascial pain and fibromyalgia syndrome. Neurology 1997;48(6):1739; author reply: 41-2
   PubMedGoogle Scholar
• Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008;9 (1 Suppl. 1):S19-30
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13(11):1153-69
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med 2007;9(2):36
   PubMedGoogle Scholar
• Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12(6):804-13
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163:628
   PubMed Web of Science ®Google Scholar
• Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80(3):533-8
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65(1):39-44
   PubMed Web of Science ®Google Scholar
• Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007;Issue 2. Art No.:CD004846. DOI: 10.1002/14651858.CD004846.pub2
   Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106(1-2):151-8
   PubMed Web of Science ®Google Scholar
• >Rehm S, >Binder A, >Boesl I, et al. A New Topical Lidocaine-Medicated Plaster For Post-Herpetic Neuralgia: Results Of A Multi-National, Double-Blind, Placebo-Controlled Efficacy And Safety Trial. 12th World Congress on Pain; 2008 August 17–22, 2008; Glasgow, UK, 2008
   Google Scholar
• Electronic Medicines Compendium. Versatis® 5% medicated plaster summary of product characteristics. emc, 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=19291 [Last accessed 17 November 2008]
   Google Scholar
• Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64(9):937-47
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36(2):236-40
   PubMed Web of Science ®Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30(2):191-7
   PubMed Web of Science ®Google Scholar
• Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9(8):1202-8
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163(5):628
   PubMed Web of Science ®Google Scholar
• Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7(1):43-8
   PubMed Web of Science ®Google Scholar
• McQuay H. Opioids in pain management. Lancet 1999;353:2229-32
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837-42
   PubMed Web of Science ®Google Scholar
• Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998;51(4):1166-71
   PubMed Web of Science ®Google Scholar
• Malonne H, Coffiner M, Fontaine D, et al. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005;30(2):113-20
   PubMed Web of Science ®Google Scholar
• Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50(6):1837-41
   PubMed Web of Science ®Google Scholar
• Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12(1):13-21
   PubMed Web of Science ®Google Scholar